Overview

A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis

Status:
Completed
Trial end date:
2020-01-16
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of mirikizumab in participants with moderate to severe plaque psoriasis.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Mirikizumab